From: Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
 |  |  |  |  | IC50 (μM) | |||
---|---|---|---|---|---|---|---|---|
Cell line | KRAS/BRAF status | MSI status | ATM and BRCA1/2 status | CMS | Niraparib | 5FU | Oxaliplatin | SN38 |
HCT15 | KRAS mut | MSI | ATM mut BRCA2 mut | CMS1 | 1.4 | 6.2 | 0.3 | 0.006 |
LOVO | KRAS mut | MSI | Â | CMS1 | 1.6 | 2 | 0.1 | 0.01 |
LIM1215 | RAS/BRAF wt | MSI | ATM mut | CMS1 | 2.3 | 5.1 | 0.8 | 0.005 |
SW48 | RAS/BRAF wt | MSI | BRCA2 mut | CMS1 | 4.3 | 5.3 | 0.2 | 0.001 |
SW1116 | KRAS mut | MSS |  | CMS2 | > 10 | 2.7 | 1 | > 1 |
LS1034 | KRAS mut | MSS | Â | CMS2 | 6.2 | 1.5 | 0.1 | 0.02 |
SW403 | KRAS mut | MSS | Â | CMS2 | 6.3 | 3.7 | 2.7 | 0.008 |
SW948 | KRAS mut | MSS | ATM mut | CMS3 | 2.8 | 14.5 | 0.1 | 0.06 |
WiDr | BRAF mut | MSS | Â | CMS3 | 8.5 | 32 | 0.8 | 0.003 |
HCT116 | KRAS mut | MSI | ATM mut | CMS4 | 1.4 | 2.2 | 0.25 | 0.005 |
SW480 | KRAS mut | MSS | ATM mut | CMS4 | 2.1 | 5.4 | 0.4 | 0.005 |
CACO2 | RAS/BRAF wt | MSS | Â | CMS4 | 8.6 | 2.2 | 0.1 | 0.01 |